These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 26717007)

  • 1. The Impact and Cost-Effectiveness of a Four-Month Regimen for First-Line Treatment of Active Tuberculosis in South Africa.
    Knight GM; Gomez GB; Dodd PJ; Dowdy D; Zwerling A; Wells WA; Cobelens F; Vassall A; White RG
    PLoS One; 2015; 10(12):e0145796. PubMed ID: 26717007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incremental Cost Effectiveness of Bedaquiline for the Treatment of Rifampicin-Resistant Tuberculosis in South Africa: Model-Based Analysis.
    Schnippel K; Firnhaber C; Conradie F; Ndjeka N; Sinanovic E
    Appl Health Econ Health Policy; 2018 Feb; 16(1):43-54. PubMed ID: 28980217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost and cost-effectiveness of tuberculosis treatment shortening: a model-based analysis.
    Gomez GB; Dowdy DW; Bastos ML; Zwerling A; Sweeney S; Foster N; Trajman A; Islam MA; Kapiga S; Sinanovic E; Knight GM; White RG; Wells WA; Cobelens FG; Vassall A
    BMC Infect Dis; 2016 Dec; 16(1):726. PubMed ID: 27905897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Scaling up target regimens for tuberculosis preventive treatment in Brazil and South Africa: An analysis of costs and cost-effectiveness.
    Nsengiyumva NP; Campbell JR; Oxlade O; Vesga JF; Lienhardt C; Trajman A; Falzon D; Den Boon S; Arinaminpathy N; Schwartzman K
    PLoS Med; 2022 Jun; 19(6):e1004032. PubMed ID: 35696431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic implications of novel regimens for tuberculosis treatment in three high-burden countries: a modelling analysis.
    Ryckman TS; Schumacher SG; Lienhardt C; Sweeney S; Dowdy DW; Mirzayev F; Kendall EA
    Lancet Glob Health; 2024 Jun; 12(6):e995-e1004. PubMed ID: 38762299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of novel first-line treatment regimens for tuberculosis.
    Owens JP; Fofana MO; Dowdy DW
    Int J Tuberc Lung Dis; 2013 May; 17(5):590-6. PubMed ID: 23575322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Health outcomes of bedaquiline in the treatment of multidrug-resistant tuberculosis in selected high burden countries.
    Lu X; Smare C; Kambili C; El Khoury AC; Wolfson LJ
    BMC Health Serv Res; 2017 Jan; 17(1):87. PubMed ID: 28122562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cost-effectiveness of a bedaquiline-containing short-course regimen for the treatment of multidrug-resistant tuberculosis in South Africa.
    Mpobela Agnarson A; Williams A; Kambili C; Mattson G; Metz L
    Expert Rev Anti Infect Ther; 2020 May; 18(5):475-483. PubMed ID: 32186925
    [No Abstract]   [Full Text] [Related]  

  • 9. Economic and modeling evidence for tuberculosis preventive therapy among people living with HIV: A systematic review and meta-analysis.
    Uppal A; Rahman S; Campbell JR; Oxlade O; Menzies D
    PLoS Med; 2021 Sep; 18(9):e1003712. PubMed ID: 34520463
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of treating multidrug-resistant tuberculosis.
    Resch SC; Salomon JA; Murray M; Weinstein MC
    PLoS Med; 2006 Jul; 3(7):e241. PubMed ID: 16796403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost utility of lateral-flow urine lipoarabinomannan for tuberculosis diagnosis in HIV-infected African adults.
    Sun D; Dorman S; Shah M; Manabe YC; Moodley VM; Nicol MP; Dowdy DW
    Int J Tuberc Lung Dis; 2013 Apr; 17(4):552-8. PubMed ID: 23485389
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Burden of non-adherence to latent tuberculosis infection drug therapy and the potential cost-effectiveness of adherence interventions in Canada: a simulation study.
    Patel AR; Campbell JR; Sadatsafavi M; Marra F; Johnston JC; Smillie K; Lester RT
    BMJ Open; 2017 Sep; 7(9):e015108. PubMed ID: 28918407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Setting priorities in health research using the model proposed by the World Health Organization: development of a quantitative methodology using tuberculosis in South Africa as a worked example.
    Hacking D; Cleary S
    Health Res Policy Syst; 2016 Feb; 14():10. PubMed ID: 26861120
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost, affordability and cost-effectiveness of strategies to control tuberculosis in countries with high HIV prevalence.
    Currie CS; Floyd K; Williams BG; Dye C
    BMC Public Health; 2005 Dec; 5():130. PubMed ID: 16343345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of adverse drug reactions on the incremental cost-effectiveness of bedaquiline for drug-resistant tuberculosis.
    Schnippel K; Firnhaber C; Page-Shipp L; Sinanovic E
    Int J Tuberc Lung Dis; 2018 Aug; 22(8):918-925. PubMed ID: 29991402
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bedaquiline-based treatment for extensively drug-resistant tuberculosis in South Africa: A cost-effectiveness analysis.
    Fekadu G; Yao J; You JHS
    PLoS One; 2022; 17(8):e0272770. PubMed ID: 35930574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Projected health and economic effects of a pan-tuberculosis treatment regimen: a modelling study.
    Ryckman TS; McQuaid CF; Cohen T; Menzies NA; Kendall EA
    Lancet Glob Health; 2024 Oct; 12(10):e1629-e1637. PubMed ID: 39159654
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of treating multidrug-resistant tuberculosis in treatment initiative centers and treatment follow-up centers in Ethiopia.
    Alemayehu S; Yigezu A; Hailemariam D; Hailu A
    PLoS One; 2020; 15(7):e0235820. PubMed ID: 32716915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modeling the patient and health system impacts of alternative xpert® MTB/RIF algorithms for the diagnosis of pulmonary tuberculosis in Addis Ababa, Ethiopia.
    Tesfaye A; Fiseha D; Assefa D; Klinkenberg E; Balanco S; Langley I
    BMC Infect Dis; 2017 May; 17(1):318. PubMed ID: 28464797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Shorter antibiotic regimens impact the control efforts in high tuberculosis burden regions of Taiwan.
    Lin YJ; Lin HC; Yang YF; Chen CY; Lu TH; Liao CM
    Int J Infect Dis; 2020 Aug; 97():135-142. PubMed ID: 32474203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.